

Price Sensitive Information

The Meeting of the Board of Directors of Beacon Pharmaceuticals PLC. held on 29th September, 2024 at 4.00 pm at its Corporate Office, BEACON Business Centre, 9/B/2, Toyenbee Circular Road, Motijheel C/A, Dhaka-1223 to approve the Audited Financial Statements of the Company for the year ended 30th June, 2024 and has taken the following decisions:

Date & time of the 23rd AGM : 23rd December, 2024, Monday at 11.00 a.m
through digital platform.

Venue of the 23rd AGM : Digital Platform

Record Date : 27th October, 2024.

Recommended Dividend : 20% Cash Dividend to General Shareholder and 10%
Cash Dividend to Sponsor Shareholder & Directors.

The Board also declared the following financial information:

Earning Per Share (EPS) : Tk. 2.26

Net Asset Value Per Share (NAVPS) : Tk. 26.37

Net Operating Cash Flow Per Share (NOCFPS) : Tk. (0.78)

The Comparative statement of financial information in respect of previous year is as follows:

Sl.No.	Particulars	Yr. 2023-24	Yr. 2022-23
01	Earning Per Share (EPS)	Tk. 2.26	Tk. 2.21
02	Net Asset Value Per Share (NAVPS)	Tk. 26.37	Tk. 25.72
03	Net Operating Cash Flow Per Share (NOCFPS)	Tk. (0.78)	Tk. 2.69

Date : 29.09.2024

By the order of the Board of Directors

BEACON[®]
Pharmaceuticals PLC

BEACON Business Centre:
9/B/2 Toyenbee Circular Road, Motijheel, Dhaka-1223

S/D

Md. Sahabuddin FCS
Company Secretary

- Hon'ble Shareholders are requested to update the particulars of their BO ID with mailing address, contact number, email ID and 12 Digit Taxpayer's Identification Number (e-TIN) through Depository Participants (DP) before the record date.
- Failure to provide e-TIN to Depository Participants, Tax to be deducted @ 15% instead of 10% (Individual) as per Section 54 of Income Tax Ordinance 1984.

3C X 6 Inch